Abeona Therapeutics Inc. (ABEO) Shares Gap Up After Analyst Upgrade

Abeona Therapeutics Inc. (NASDAQ:ABEO) shares gapped up prior to trading on Wednesday after Cantor Fitzgerald raised their price target on the stock from $21.00 to $34.00. The stock had previously closed at $21.90, but opened at $19.95. Cantor Fitzgerald currently has an overweight rating on the stock. Abeona Therapeutics shares last traded at $19.40, with a volume of 1,823,352 shares.

ABEO has been the subject of several other research reports. Zacks Investment Research cut Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Monday. Royal Bank Of Canada started coverage on Abeona Therapeutics in a research report on Thursday, September 14th. They issued an “outperform” rating and a $23.00 price objective for the company. Maxim Group set a $17.00 price objective on Abeona Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, August 29th. Finally, BidaskClub upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $21.44.

Several hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares in the last quarter. Ardsley Advisory Partners increased its position in shares of Abeona Therapeutics by 33.3% in the second quarter. Ardsley Advisory Partners now owns 60,000 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 15,000 shares in the last quarter. State of Wisconsin Investment Board purchased a new position in shares of Abeona Therapeutics in the second quarter valued at $122,000. Bank of New York Mellon Corp increased its position in shares of Abeona Therapeutics by 125.8% in the first quarter. Bank of New York Mellon Corp now owns 41,929 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 23,358 shares in the last quarter. Finally, Family Management Corp purchased a new position in shares of Abeona Therapeutics in the first quarter valued at $120,000. Institutional investors and hedge funds own 38.38% of the company’s stock.

The stock’s market capitalization is $707.04 million. The firm’s 50-day moving average price is $15.16 and its 200 day moving average price is $8.64.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Tuesday, August 15th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.07). The firm had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative net margin of 2,746.38% and a negative return on equity of 26.66%. On average, equities analysts forecast that Abeona Therapeutics Inc. will post ($0.70) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.themarketsdaily.com/2017/10/13/abeona-therapeutics-inc-abeo-shares-gap-up-after-analyst-upgrade.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply